Premedication and Chemotherapy Agents Do Not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-2579
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)


Related search